- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03272113
SKIP-IT Smoking Cessation in Pregnancy (SKIP-IT)
Promoting Smoking Cessation During Pregnancy: a Combined Feasibility and Pilot Trial of a Theory-based Intervention Using Narrative, Images and Embedded Behaviour Change Techniques, Delivered Via Text-messaging
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Smoking during pregnancy carries serious risks to mother and infant health. More babies whose mothers smoke are stillborn or die within the first year of life. Smoking during pregnancy results in increased rates of intrauterine growth retardation, preterm birth, and babies' longer-term risk of developing heart disease and diabetes. Pregnant women who smoke are more likely to experience miscarriage, placental abruption, pregnancy-induced hypertension and later conditions such as lung cancer and heart disease.
Reduction in smoking in pregnancy has been a long standing health policy target however there is limited evidence of effectiveness of many smoking cessation interventions and their uptake is generally low. We have developed, and carried out initial testing of an intervention to support smoking cessation in pregnant women using narrative, story-telling delivered via automated text-messages. The intervention aims to alter women's perceptions of risk, social norms, outcomes and self-efficacy using three key elements. 1. a narrative story of a fictional young pregnant woman 'Megan' trying to stop smoking by overcoming a series of commonplace barriers. 2) images showing the size of their fetus and its stage of development 3) an interactive 'help' function to receive a supportive, tailored response. Behaviour change techniques for smoking cessation in pregnancy are embedded in the intervention.
A randomised controlled trial is required to test the effectiveness of the intervention in reducing smoking in pregnancy. The aim of this study is to investigate the feasibility and likelihood of success of the narrative and image-based intervention for smoking cessation in pregnant women. If successful the intervention will be tested in a full-scale (Phase III) multi centre randomised controlled trial.
Objectives:
- To assess acceptability and willingness to be randomised to the narrative and image based intervention or usual care.
- To assess and compare the feasibility of recruitment strategies, the level of participants' retention in the study and engagement with the intervention.
- To assess the acceptability and likely impact of the intervention among pregnant smokers.
- To estimate the required sample size for a full trial.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Ayr, Reino Unido
- NHS Ayrshire and Arran
-
Perth, Reino Unido
- NHS Tayside
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Women 16 years of age or over,
- Live within the catchment areas of study sites,
- Up to and including 14 weeks of pregnancy,
- Current smoker,
- Own or regularly use a mobile phone with media capability,
- Understand written English,
- Able to give informed consent.
Exclusion Criteria:
- Women who do not currently smoke,
- Live outside the catchment areas of study sites,
- Over 14 weeks of pregnancy,
- Do not use or have access to a mobile phone with media capability,
- Cannot understand written English,
- Not able to give informed consent,
- Already enrolled in an alternative formal smoking cessation trial at the time of referral to the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Control
Usual care to provided by smoking cessation services in the two study sites. Site one: support from a specialist advisor using motivational interviewing, one to one, group and telephone support. Site two: a smoking cessation incentive scheme administered through community pharmacies. Women who are verified by CO testing to have stopped smoking receive £12.50 per week. |
|
|
Experimental: Intervention
Women will receive usual care as described above plus the SKIP-IT intervention
|
A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recruitment rate
Periodo de tiempo: 23 months
|
Progression to a full trial will require recruitment ≥50% of women who give permission to have their details passed to the research team (i.e.
those who express initial interest in the study).
|
23 months
|
|
Drop out rate
Periodo de tiempo: 23 months
|
Progression to a full trial will require <30% dropout
|
23 months
|
|
Direction of effect
Periodo de tiempo: 23 months
|
Progression to a full trial will require direction of effect on smoking cessation rate in favour of the intervention.
|
23 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Engagement
Periodo de tiempo: 23 months
|
Engagement in the intervention will be assessed using data captured by the computer system which monitors the text message responses.
|
23 months
|
|
Acceptability
Periodo de tiempo: 23 months
|
Acceptability of the intervention will be assessed in short interviews conducted with intervention group participants at the follow-up points
|
23 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Smoking cessation outcomes
Periodo de tiempo: At each subsequent data collection time-point (4 weeks post-randomisation, 36 weeks of pregnancy, 6-7 weeks post due-date, 12-13 weeks post due-date)
|
|
At each subsequent data collection time-point (4 weeks post-randomisation, 36 weeks of pregnancy, 6-7 weeks post due-date, 12-13 weeks post due-date)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- RMS2119
- HIPS/16/4 (Otro número de subvención/financiamiento: Scottish Government Chief Scientist Office)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre SKIP-IT
-
University of WashingtonNational Institute of Nursing Research (NINR)TerminadoAsma | Alteración del sueñoEstados Unidos
-
Oslo University HospitalCentre for Appearance Research, University of the West of England, UKInscripción por invitaciónQuemaduras | Labio y paladar hendido | Anomalías craneofaciales | Condición de piel | Otras condiciones que conducen a una diferencia visibleNoruega
-
Integro TheranosticsTerminadoCáncer de mama | CDIS | Carcinoma ductal invasivo de mamaEstados Unidos
-
ShireTerminadoSíndrome del cazadorEstados Unidos, Reino Unido
-
Philips Clinical & Medical Affairs GlobalTerminadoEnfermedad Arterial Periférica | Isquemia Crítica de las ExtremidadesAustria
-
Liverpool School of Tropical MedicineKenya Medical Research Institute; LVCT HealthReclutamientoEl embarazo | Sistemas de Salud | Sistemas electrónicos de información de salud comunitaria | Aceptación de la clínica prenatalKenia
-
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd...Beijing Tiantan HospitalReclutamientoAccidente cerebrovascular isquémicoPorcelana
-
TakedaTerminadoSíndrome del cazadorEstados Unidos, Reino Unido, Canadá
-
Oregon Health and Science UniversityTexas A&M University; University of North Carolina, GreensboroActivo, no reclutandoActividad físicaEstados Unidos
-
University of Alabama at BirminghamNational Institute on Aging (NIA)Activo, no reclutandoDemencia | Comportamiento resistente al cuidadoEstados Unidos